Clinical validation of p16/Ki‐67 dual‐stained cytology triage of HPV‐positive women: Results from the IMPACT trial
Open Access
- 18 September 2021
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 150 (3) , 461-471
Abstract
Triage strategies are needed for primary human papillomavirus (HPV)‐based cervical cancer screening to identify women requiring colposcopy/biopsy. We assessed the performance of p16/Ki‐67 dual‐stained (DS) immunocytochemistry to triage HPV‐positive women and compared it to cytology, with or without HPV16/18 genotyping. A prospective observational screening study enrolled 35 263 women aged 25 to 65 years at 32 U.S. sites. Cervical samples had HPV and cytology testing, with colposcopy/biopsy for women with positive tests. Women without cervical intraepithelial neoplasia Grade 2 or worse (≥CIN2) at baseline (n = 3876) were retested after 1 year. In all, 4927 HPV‐positive women with valid DS results were included in this analysis. DS sensitivity for ≥CIN2 and ≥CIN3 at baseline was 91.2% (95% confidence interval [CI]: 86.8%‐94.2%) and 91.9% (95% CI: 86.1%‐95.4%), respectively, in HPV16/18‐positive women and 83.0% (95% CI: 78.4%‐86.8%) and 86.0% (95% CI: 77.5%‐91.6%) in women with 12 “other” genotypes. Using DS alone to triage HPV‐positive women showed significantly higher sensitivity and specificity than HPV16/18 genotyping with cytology triage of 12 “other” genotypes, and substantially higher sensitivity but lower specificity than using cytology alone. The risk of ≥CIN2 was significantly lower in HPV‐positive, DS‐negative women (3.6%; 95% CI: 2.9%‐4.4%), compared to triage‐negative women using HPV16/18 genotyping with cytology for 12 “other” genotypes (7.4%; 95% CI: 6.4%‐8.5%; P < .0001) or cytology alone (7.5%; 95% CI: 6.7%‐8.4%; P < .0001). DS showed better risk stratification than cytology‐based strategies and provided high reassurance against pre‐cancers both at baseline and at 1‐year follow‐up, irrespective of the HPV genotype. DS allows for the safe triage of primary screening HPV‐positive women.Keywords
Funding Information
- Roche
This publication has 25 references indexed in Scilit:
- Prospective evaluation of p16/Ki‐67 dual‐stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study resultsCancer Cytopathology, 2015
- Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidanceGynecologic Oncology, 2015
- Primary cervical cancer screening with human papillomavirus: End of study results from the ATHENA study using HPV as the first-line screening testGynecologic Oncology, 2015
- Interpretation of p16INK4a/Ki‐67 dual immunostaining for the triage of human papillomavirus‐positive women by experts and nonexperts in cervical cytologyCancer Cytopathology, 2014
- Screening for Cervical Cancer Precursors With p16/Ki-67 Dual-Stained Cytology: Results of the PALMS StudyJNCI: Journal of the National Cancer Institute, 2013
- The ATHENA human papillomavirus study: design, methods, and baseline resultsAmerican Journal of Obstetrics and Gynecology, 2012
- Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA studyThe Lancet Oncology, 2011
- Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytologyGynecologic Oncology, 2011
- Bootstrap confidence intervalsStatistical Science, 1996
- Confidence Limits for the Ratio of Two Binomial Proportions Based on Likelihood Scores: Non‐Iterative MethodBiometrical Journal, 1995